Last updated on December 2019

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

Brief description of study

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

Clinical Study Identifier: NCT03798626

Find a site near you

Start Over

Novartis Investigative Site

Ramat Gan, Israel
  Connect »

Novartis Investigative Site

Tel Aviv, Israel
  Connect »